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ABSTRACT
Background
Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in
adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors
gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating
mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be
mutually exclusive.
Methods and Findings
We sought to determine whether mutations in KRAS could be used to further enhance
prediction of response to gefitinib or erlotinib. We screened 60 lung adenocarcinomas defined
as sensitive or refractory to gefitinib or erlotinib for mutations in EGFR and KRAS. We show that
mutations in KRAS are associated with a lack of sensitivity to either drug.
Conclusion
Our results suggest that treatment decisions regarding use of these kinase inhibitors might
be improved by determining the mutational status of both EGFR and KRAS.
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Genes of the ERBB family encode receptor tyrosine kinases
that mediate cellular responses to growth signals. Somatic
mutations in the tyrosine kinase domains of two ERBB genes,
epidermal growth factor receptor (EGFR) and HER2, have been
found in a proportion of lung adenocarcinomas [1,2,3,4]. For
EGFR, mutations are associated with sensitivity to the small-
molecule kinase inhibitors geﬁtinib (Iressa) [1,2,3] and
erlotinib (Tarceva) [3].
ERBB signaling pathways include downstream GTPases
encoded by RAS genes. Some 15%–30% of lung adenocarci-
nomas contain activating mutations in the RAS family
member KRAS. These mutations are most frequently found
in codons 12 and 13 in exon 2 [5,6], and may be associated
with unfavorable outcomes [7]. Interestingly, EGFR and KRAS
mutations are rarely found in the same tumors, suggesting
that they have functionally equivalent roles in lung tumori-
genesis ([8]; M. Meyerson, personal communication). Fur-
thermore, EGFR mutations are common in tumors from
patients who have smoked less than 100 cigarettes in their
lifetimes (‘‘never smokers’’) [3], while KRAS mutations more
commonly occur in individuals with a history of substantial
cigarette use [9].
We sought to determine whether KRAS mutations could
also be used to predict primary sensitivity or resistance to
geﬁtinib or erlotinib. We systematically evaluated 60 lung
adenocarcinomas from patients with known responses to
either of these drugs for the presence of mutations in EGFR
(exons 18 through 21) and KRAS2 (exon 2). Here, we show
that mutations in KRAS are associated with primary
resistance to single-agent geﬁtinib or erlotinib. Our results
suggest that a determination of mutational status for both
EGFR and KRAS may help deﬁne which patients are likely to
beneﬁt from receiving geﬁtinib or erlotinib.
Methods
Tissue Procurement
Tumor specimens were obtained through protocols ap-
proved by the institutional review board of Memorial Sloan-
Kettering Cancer Center, as previously described [3] (see
Protocols S1–S3). Tumor material, obtained from patients
prior to kinase inhibitor treatment for lung cancer, was
collected retrospectively for patients on geﬁtinib, who
received 250 mg or 500 mg orally once daily (n = 24), and
prospectively for patients on erlotinib, who received 150 mg
orally once daily (n = 36). The latter cohort of patients was
part of a clinical trial of erlotinib for patients with
bronchioloalveolar carcinoma. The analysis presented here
includes specimens we previously reported on (n = 17 for
geﬁtinib and n = 17 for erlotinib) [3].
All specimens were reviewed by a single reference
pathologist (M. F. Z.). Imaging studies were assessed by a
single reference radiologist (R. T. H.), who graded responses
according to Response Evaluation Criteria in Solid Tumors
(RECIST) [10]. Both observers were blinded to patient
outcomes.
Eight of nine patients with tumors sensitive to geﬁtinib
had objective partial responses as deﬁned by RECIST, i.e., at
least a 30% decrease in the sum of the longest diameters of
target lesions, taking as reference the sum measured at
baseline. The ninth patient had marked clinical improve-
ment, as ascertained by two independent reviewing physi-
cians and manifested by lessened dyspnea and cancer-
related pain. However, this individual had radiographic
lesions (pleural and bone metastases) that were deemed
nonmeasurable by RECIST criteria. As erlotinib-treated
patients were all in a clinical trial, all had disease
measurable using RECIST guidelines. For both drugs in this
study, tumors were considered refractory if they did not
undergo sufﬁcient shrinkage to qualify for partial response.
This deﬁnition includes patients whose ‘‘best overall
response’’ was either progression of disease (n = 26) or
stable disease (n = 12) as deﬁned by RECIST. No patients
had a complete response.
Mutational Analyses of EGFR and KRAS in Lung Tumors
Genomic DNA was extracted from tumors embedded in
parafﬁn blocks, except for tumor 109T, which was a fresh-
frozen tumor specimen. Primers for EGFR analyses (exons
18–21) were as published [3]. For KRAS analyses, the following
nested primer sets for exon 2 were used: huKRAS2 ex2F, 59-
GAATGGTCCTGCACCAGTAA-39; huKRAS2 ex2R, 59-
GTGTGACATGTTCTAATATAGTCA-39; huKRAS2 ex2Fint,
59-GTCCTGCACCAGTAATATGC-39; and huKRAS2 ex2Rint,
59-ATGTTCTAATATAGTCACATTTTC-39.
For both EGFR and KRAS, PCR was performed using the
HotStarTaq Master Mix Kit (Qiagen, Valencia, California,
United States), as per manufacturer’s instructions. Use of this
method often obviated the need for nested PCR sets. All
sequencing reactions were performed in both forward and
reverse directions, and all mutations were conﬁrmed by PCR
ampliﬁcation of an independent DNA isolate.
In 12 cases, exon 19 deletions were also studied by length
analysis of ﬂuorescently labeled PCR products on a capillary
electrophoresis device, using the following primers: EGFR-
Ex19-FWD1, 59-GCACCATCTCACAATTGCCAGTTA-39, and
EGFR-Ex19-REV1, 59-Fam-AAAAGGTGGGCCTGAGGTTCA-
39. Using serial dilutions of DNA from the H1650 non-small-
cell lung cancer cell line (exon 19 deletion-positive [11]), this
assay detects the mutant allele when H1650 DNA comprises
Table 1. EGFR and KRAS Mutation Status in Lung Adenocarci-
nomas Sensitive or Refractory to Gefitinib or Erlotinib
Drug Gene
Mutated
Proportion
Sensitive
Proportion
Refractory
p-Value
Gefitinib EGFR 9/12 0/12 0.0034
KRAS 0/12 5/12 0.0373
Erlotinib EGFR 8/10 0/26 1.487 3 10
 6
KRAS 0/9
a 4/26 0.5531
b
Gefitinib or Erlotinib EGFR 17/22 0/38 6.801 3 10
 11
KRAS 0/21
a 9/38 0.0201
Lung tumors were examined for mutations in EGFR (exons 18–21) and KRAS (exon 2). In gefitinib-treated patients, six
EGFR mutations involved exon 19 deletions that lacked the amino acids Leu-Arg-Glu-Ala, and two were exon 21
amino acid substitutions (L858R). A seventh case with an exon 19 deletion (involving 12 nucleotides) was detected
by fluorescent capillary electrophoresis only, so exact sequence deletion information was unavailable (see Methods).
In erlotinib-treated patients, three EGFR mutations were exon 19 deletions that lacked amino acids Leu-Arg-Glu-Ala,
and five were exon 21 amino acid substitutions (L858R).
a One erlotinib-sensitive tumor was unavailable for KRAS examination.
b The incidence of KRAS mutations in this cohort was low, probably because only cases involving bronchioloalveolar
carcinoma were tested (see text).
DOI: 10.1371/journal.pmed.0020017.t001
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KRAS Mutations Predict Drug Resistance6% or more of the total DNA tested, compared to a sensitivity
of 12% for direct sequencing. These same cases were also
screened for the exon 21 L858R mutation by a PCR–
restriction fragment length polymorphism assay, based on a
new Sau96I restriction site created by the L858R mutation
(2,573T!G). The Sau96I-digested ﬂuorescently labeled PCR
products were analyzed by capillary electrophoresis, and the
following primers were used: EGFR-Ex21-FWD1, 59-CCTCA-
CAGCAGGGTCTTCTCTGT-39,a n dEGFR-Ex21-REV1, 59-
Fam-TCAGGAAAATGCTGGCTGACCTA-39. Using serial di-
lutions of DNA from the H1975 cell line (L858R-positive [11]),
this assay detects the mutant allele when H1975 DNA
comprises 3% or more of the total DNA tested, compared
to a sensitivity of 6% for direct sequencing (Q. Pan, W. Pao,
and M. Ladanyi, unpublished data).
Statistics
Fisher’s Exact Test was used to calculate p-values, and
conﬁdence intervals were calculated using Statistics with
Conﬁdence software [12].
Results
We identiﬁed 60 lung adenocarcinomas from individual
patients with tumors shown to be sensitive or refractory to
single-agent geﬁtinib or erlotinib and evaluated these
tumors for mutations in EGFR and KRAS. Collectively, nine
Figure 1. Sequence Chromatograms Displaying the Types of KRAS Mutations Found in This Study
DOI: 10.1371/journal.pmed.0020017.g001
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KRAS Mutations Predict Drug Resistanceof 38 (24%) tumors refractory to either kinase inhibitor had
KRAS mutations, while zero of 21 (0%) drug-sensitive tumors
had such mutations (p = 0.02) (Table 1). The 95%
conﬁdence intervals (CIs) for these observations are 13%–
39% and 0%–16%, respectively. Conversely, 17 of 22 (77%)
tumors sensitive to either kinase inhibitor had EGFR
mutations, in contrast to zero of 38 (0%) drug-resistant
tumors (p = 6.8 3 10
 11). The 95% CIs for these observed
response rates are 57%–90% and 0%–9%, respectively. All
17 tumors with EGFR mutations responded to geﬁtinib or
erlotinib, while all nine tumors with KRAS mutations did not
(p = 3.2 3 10
 7).
Correlation of EGFR and KRAS mutational status with drug
and treatment response is detailed in Table 1. The spectrum
of KRAS mutations is shown in Figure 1 and Table 2. Results
with geﬁtinib and erlotinib were similar overall. However, the
incidence of KRAS mutations in the patients treated with
erlotinib was low, probably because of the fact that all
patients treated with this drug had bronchioloalveolar
carcinoma, which rarely has RAS mutations [13]. Alterna-
tively, our analyses involving only exon 2 of KRAS2 may have
missed some RAS mutations. However, in our analysis of the
exonic regions encoding the ﬁrst 100 amino acids of KRAS in
110 surgically resected early-stage non-small-cell lung can-
cers, we have found 18 mutations, and all were in either
codon 12 or codon 13, encoded by exon 2 (W. Pao, R. Wilson,
H. Varmus, unpublished data). Another possibility is that the
erlotinib-treated tumors have mutations in other RAS genes,
since a minority of RAS mutations in lung cancer have been
reported to occur in N- or HRAS [5,6].
Discussion
These results have important clinical implications. First,
they extend previous data from our group and others
showing that lung adenocarcinomas containing EGFR muta-
tions are associated with sensitivity to geﬁtinib or erlotinib
(17 of 17 in this series; 100% observed response rate; 95% CI,
82%–100%). Second, these data show that tumors with KRAS
exon 2 mutations (n = 9) are associated with a lack of
response to these kinase inhibitors (0% observed response
rate; 95% CI, 0%–30%). Third, no drug-sensitive tumors had
KRAS exon 2 mutations (n = 21). Whether KRAS mutational
status can be used to predict responses to geﬁtinib or
erlotinib in patients whose tumors have wild-type EGFR
sequence is still under investigation: our analysis comparing
response rates for tumors with neither EGFR nor KRAS
mutations versus tumors with wild-type EGFR but mutated
KRAS does not reach statistical signiﬁcance (ﬁve of 22 versus
zero of nine; p = 0.29). Nevertheless, these ﬁndings suggest
that patients whose lung adenocarcinomas have KRAS
mutations will not experience signiﬁcant tumor regression
with either drug.
The incidence of EGFR mutations in tumors responsive to
EGFR kinase inhibitors has varied from 71% to 100% ([1,2,3]
and this paper). Thus, at this point, patients whose tumors
test negative for EGFR mutations should not necessarily be
precluded from treatment with either geﬁtinib or erlotinib.
Data presented here suggest that clinical decisions regarding
the use of these agents in patients with lung adenocarcinomas
might be improved in the future by pre-treatment mutational
proﬁling of both EGFR and KRAS. These ﬁndings warrant
validation in large prospective trials using standardized
mutation detection techniques.
Supporting Information
Protocol S1. Preclinical Studies of Blood, Urine, Bone Marrow, and
Tissues Collected from Patients with Thoracic Malignancies
Found at DOI: 10.1371/journal.pmed.0020017.sd001 (32 KB PDF).
Protocol S2. Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva)
in Patients with Advanced Bronchioloalveolar Cell Lung Cancer
Found at DOI: 10.1371/journal.pmed.0020017.sd002 (1.9 MB PDF).
Protocol S3. Protocol Approval Letters
Found at DOI: 10.1371/journal.pmed.0020017.sd003 (60 KB PDF).
Accession Numbers
The LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink/) accession
number for the KRAS2 sequence discussed in this paper is 3845;
the GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
ber for the KRAS2 sequence discussed in this paper is
NT_009714.16.
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Patient Summary
Background Two drugs, gefitinib (Iressa) and erlotinib (Tarceva), have
been developed that can make lung cancers smaller in some patients.
The drugs work by blocking the effect of a molecule called the epidermal
growth factor receptor (EGFR), which relays instructions to cells to grow
and divide. Recently, researchers found that these drugs most effectively
shrink tumors that have acquired abnormal variations (mutations) in the
EGFR gene. These mutations somehow allow tumor cells to escape
normal safety mechanisms that keep cells from growing out of control.
Some lung cancers also have mutations in another gene called KRAS.
Interestingly, KRAS mutations and EGFR mutations are rarely ever found
in the same tumor.
Why Was This Study Done? Unfortunately, EGFR mutations are only
found in a minority of patients with lung cancer. This means that
gefitinib or erlotinib might be given to a lot of patients who may not
benefit from this treatment. Ideally, the drugs would be given only to
patients who we know will benefit from them. This study examined
whether studying the KRAS gene (to see if it had a mutation) could help
predict which patients had tumors that would respond well to the drugs.
What Did the Researchers Do? They took 60 lung cancer samples from
patients who had been treated with one of the drugs and either
responded (that is, their tumors shrunk in size) or not, and tested
whether the tumors had normal or abnormal KRAS.
What Did They Find? Tumors that got significantly smaller while
treated with gefitinib or erlotinib (a total of 22) had a normal KRAS gene.
Most of these tumors had EGFR mutations. Conversely, tumors that had
abnormal KRAS (a total of nine) did not shrink while treated with gefitinib
or erlotinib.
What Does This Mean? Both gefitinib and erlotinib are expensive and
have side effects. Testing for EGFR and KRAS mutations is relatively
straightforward, and one could test for abnormalities in both genes first
and then decide which patients should be treated with either of the two
drugs.
What Next? Before doing EGFR and KRAS tests on a routine basis and
taking the results into account when making a decision about who
should be treated with gefitinib or erlotinib, larger studies need to be
done to see whether the results reported here hold up.
More Information Online
US Food and Drug Administration information page on Iressa: http://
www.fda.gov/cder/drug/infopage/iressa/iressaQ&A.htm
Cancer Research UK information page about erlotinib: http://www.
cancerhelp.org.uk/help/default.asp?page=10296
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